PE20220766A1 - Agonistas de receptor de melanocortina-4 - Google Patents
Agonistas de receptor de melanocortina-4Info
- Publication number
- PE20220766A1 PE20220766A1 PE2021001938A PE2021001938A PE20220766A1 PE 20220766 A1 PE20220766 A1 PE 20220766A1 PE 2021001938 A PE2021001938 A PE 2021001938A PE 2021001938 A PE2021001938 A PE 2021001938A PE 20220766 A1 PE20220766 A1 PE 20220766A1
- Authority
- PE
- Peru
- Prior art keywords
- compound
- melanocortin
- receptor agonists
- carbonyl
- isobutyramide
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Referido a un compuesto de la siguiente Formula 1, caracterizado porque R1 es alquilo de C2-C5, o una sal o isomero farmaceuticamente aceptable del mismo. Un compuesto seleccionado es N-((3S,5S)-1-((3S,4R)-1-(ter-butil)-4-(4-clorofenil)-pirrolidin-3-carbonil)-5-(morfolin-4-carbonil)pirrolidin-3-il)- N-((1s,4R)-4-metilciclohexil)isobutiramida. Este compuesto es agonista de receptor de melanocortina-4. Tambien se refiere a una composicion farmaceutica que comprende dicho compuesto y su uso en la prevencion o el tratamiento de la obesidad, diabetes, inflamacion y disfuncion erectil.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20190141649 | 2019-11-07 | ||
| PCT/KR2020/015462 WO2021091283A1 (en) | 2019-11-07 | 2020-11-06 | Melanocortin-4 receptor agonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20220766A1 true PE20220766A1 (es) | 2022-05-16 |
Family
ID=75848091
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2021001938A PE20220766A1 (es) | 2019-11-07 | 2020-11-06 | Agonistas de receptor de melanocortina-4 |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US20220289731A1 (es) |
| EP (1) | EP3953327B1 (es) |
| JP (2) | JP7467510B2 (es) |
| KR (1) | KR102485182B1 (es) |
| CN (2) | CN113939500B (es) |
| AU (1) | AU2020377805B2 (es) |
| BR (1) | BR112021022497A2 (es) |
| CA (1) | CA3135543C (es) |
| CL (1) | CL2021003409A1 (es) |
| CO (1) | CO2021017401A2 (es) |
| DK (1) | DK3953327T3 (es) |
| ES (1) | ES2970510T3 (es) |
| FI (1) | FI3953327T3 (es) |
| HU (1) | HUE064968T2 (es) |
| IL (2) | IL288921B1 (es) |
| MX (2) | MX2021014074A (es) |
| MY (1) | MY200113A (es) |
| PE (1) | PE20220766A1 (es) |
| PH (1) | PH12021553170A1 (es) |
| PL (1) | PL3953327T3 (es) |
| PT (1) | PT3953327T (es) |
| SG (1) | SG11202112163XA (es) |
| SI (1) | SI3953327T1 (es) |
| TW (1) | TWI754448B (es) |
| UA (1) | UA127255C2 (es) |
| WO (1) | WO2021091283A1 (es) |
| ZA (1) | ZA202110474B (es) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20250179016A1 (en) * | 2020-10-29 | 2025-06-05 | Lg Chem, Ltd. | Amorphous melanocortin-4 receptor agonist |
| PE20240048A1 (es) * | 2020-10-29 | 2024-01-09 | Lg Chemical Ltd | Forma cristalina i del compuesto agonista de receptor de melanocortina y metodo de preparacion para la misma |
| CA3195432A1 (en) * | 2020-10-29 | 2022-05-05 | Jin Ok HAM | Crystalline form ii of melanocortin receptor agonist compound and preparation method therefor |
| PE20240367A1 (es) * | 2020-10-29 | 2024-03-04 | Lg Chemical Ltd | Forma cristalina iv del compuesto agonista de receptor de melanocortina y metodo de preparacion para la misma |
| KR102672626B1 (ko) * | 2020-10-29 | 2024-06-07 | 주식회사 엘지화학 | 멜라노코르틴 수용체 작용제 화합물의 결정형 ⅲ 및 이의 제조방법 |
| CN116782877A (zh) * | 2020-12-22 | 2023-09-19 | 株式会社Lg化学 | 作为黑皮质素-4受体的选择性激动剂的用途 |
| JP7662796B2 (ja) * | 2020-12-22 | 2025-04-15 | エルジー・ケム・リミテッド | 無定形のメラノコルチン受容体アゴニストおよびその製造方法 |
| EP4249484A4 (en) * | 2020-12-22 | 2024-05-15 | Lg Chem, Ltd. | Crystal type ii of melanocortin receptor agonist compound and method for preparing same |
| TWI810757B (zh) * | 2020-12-22 | 2023-08-01 | 南韓商Ｌｇ化學股份有限公司 | 黑皮質素受體促效劑化合物的晶型ｉ及其製備方法 |
| EP4249485A4 (en) * | 2020-12-22 | 2024-05-15 | Lg Chem, Ltd. | CRYSTALLINE FORM III OF A MELANOCORTIN RECEPTOR AGONIST COMPOUND AND METHOD OF PREPARING THE SAME |
| EP4275687A4 (en) * | 2021-01-21 | 2024-07-17 | Lg Chem, Ltd. | Uses of melanocortin-4 receptor agonist |
| JP7708869B2 (ja) * | 2021-02-26 | 2025-07-15 | エルジー・ケム・リミテッド | メラノコルチン－４受容体アゴニスト |
| KR102854595B1 (ko) * | 2021-05-06 | 2025-09-03 | 주식회사 엘지화학 | 멜라노코르틴 수용체 작용제 화합물의 결정형 v 및 이의 제조방법 |
| EP4317150A4 (en) * | 2021-05-06 | 2024-10-30 | Lg Chem, Ltd. | CRYSTAL FORM VII OF A MELANOCORTIN RECEPTOR AGONIST COMPOUND AND METHOD FOR THE PREPARATION THEREOF |
| JP2024516739A (ja) * | 2021-05-07 | 2024-04-16 | エルジー・ケム・リミテッド | メラノコルチン受容体アゴニスト化合物とバニリンの共結晶およびその製造方法 |
| CA3217468A1 (en) * | 2021-05-07 | 2022-11-10 | Lg Chem, Ltd. | Crystal form iv of organic acid salts of melanocortin receptor agonist compound, and preparation method thereof |
| MX2023013128A (es) * | 2021-05-07 | 2023-11-28 | Lg Chemical Ltd | Cristales de sulfato de compuesto agonista del receptor de melanocortina, y metodo para producir los mismos. |
| TWI838114B (zh) * | 2022-02-08 | 2024-04-01 | 南韓商Ｌｇ化學股份有限公司 | 黑皮質素-4受體激動劑在預防或治療罕見遺傳性肥胖中的用途 |
| TWI861780B (zh) * | 2022-03-28 | 2024-11-11 | 南韓商Ｌｇ化學股份有限公司 | 預防或治療肥胖的聯合療法 |
| WO2025149985A1 (en) * | 2024-01-10 | 2025-07-17 | Lg Chem, Ltd. | Methods of preparing melanocortin 4 receptor agonists |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2403686C (en) * | 2000-03-23 | 2010-01-26 | Merck & Co., Inc. | Substituted piperidines as melanocortin receptor agonists |
| GB0019359D0 (en) * | 2000-08-07 | 2000-09-27 | Melacure Therapeutics Ab | Novel guanidines |
| CA2439152C (en) | 2001-02-28 | 2008-06-17 | Merck & Co., Inc. | Acylated piperidine derivatives as melanocortin-4 receptor agonists |
| AR044510A1 (es) | 2003-04-14 | 2005-09-14 | Merck & Co Inc | Procedimiento e intermedios para preparar acidos carboxilicos de pirrolidina |
| CA2545644C (en) * | 2003-11-12 | 2011-11-01 | Lg Life Sciences Ltd. | Melanocortin receptor agonists |
| TWI332501B (en) * | 2006-07-14 | 2010-11-01 | Lg Life Sciences Ltd | Melanocortin receptor agonists |
| UA99555C2 (en) * | 2008-11-12 | 2012-08-27 | Элджи Лайф Саенсез Лтд. | Melanocortin receptor agonists |
| US9981960B2 (en) | 2014-05-29 | 2018-05-29 | Mitsubishi Tanabe Pharma Corporation | Pyrrolidine compound and application as melanocortin receptor agonist |
| PE20240367A1 (es) * | 2020-10-29 | 2024-03-04 | Lg Chemical Ltd | Forma cristalina iv del compuesto agonista de receptor de melanocortina y metodo de preparacion para la misma |
-
2020
- 2020-11-06 PE PE2021001938A patent/PE20220766A1/es unknown
- 2020-11-06 CA CA3135543A patent/CA3135543C/en active Active
- 2020-11-06 KR KR1020200147564A patent/KR102485182B1/ko active Active
- 2020-11-06 AU AU2020377805A patent/AU2020377805B2/en active Active
- 2020-11-06 MX MX2021014074A patent/MX2021014074A/es unknown
- 2020-11-06 BR BR112021022497A patent/BR112021022497A2/pt unknown
- 2020-11-06 MY MYPI2021006480A patent/MY200113A/en unknown
- 2020-11-06 PL PL20885384.6T patent/PL3953327T3/pl unknown
- 2020-11-06 JP JP2021575455A patent/JP7467510B2/ja active Active
- 2020-11-06 ES ES20885384T patent/ES2970510T3/es active Active
- 2020-11-06 SI SI202030361T patent/SI3953327T1/sl unknown
- 2020-11-06 HU HUE20885384A patent/HUE064968T2/hu unknown
- 2020-11-06 US US17/619,893 patent/US20220289731A1/en active Pending
- 2020-11-06 WO PCT/KR2020/015462 patent/WO2021091283A1/en not_active Ceased
- 2020-11-06 TW TW109138853A patent/TWI754448B/zh active
- 2020-11-06 EP EP20885384.6A patent/EP3953327B1/en active Active
- 2020-11-06 PH PH1/2021/553170A patent/PH12021553170A1/en unknown
- 2020-11-06 PT PT208853846T patent/PT3953327T/pt unknown
- 2020-11-06 SG SG11202112163XA patent/SG11202112163XA/en unknown
- 2020-11-06 UA UAA202107381A patent/UA127255C2/uk unknown
- 2020-11-06 DK DK20885384.6T patent/DK3953327T3/da active
- 2020-11-06 CN CN202080042935.XA patent/CN113939500B/zh active Active
- 2020-11-06 FI FIEP20885384.6T patent/FI3953327T3/fi active
- 2020-11-06 CN CN202411443355.8A patent/CN119775187A/zh active Pending
-
2021
- 2021-11-17 MX MX2024014692A patent/MX2024014692A/es unknown
- 2021-12-12 IL IL288921A patent/IL288921B1/en unknown
- 2021-12-15 ZA ZA2021/10474A patent/ZA202110474B/en unknown
- 2021-12-17 CL CL2021003409A patent/CL2021003409A1/es unknown
- 2021-12-17 CO CONC2021/0017401A patent/CO2021017401A2/es unknown
-
2024
- 2024-01-19 JP JP2024006796A patent/JP7776546B2/ja active Active
-
2025
- 2025-10-13 IL IL323922A patent/IL323922A/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20220766A1 (es) | Agonistas de receptor de melanocortina-4 | |
| RU2374241C2 (ru) | N-ацилированные азотсодержащие гетероциклические соединения в качестве лигандов ppar-рецепторов, активируемых пролифератором пероксисомы | |
| PE20211810A1 (es) | Compuestos novedosos | |
| PE20180160A1 (es) | Sulfonilureas y compuestos relacionados y uso de estos | |
| PE20231379A1 (es) | Agonista de receptor de melanocortina-4 amorfo | |
| CO2019002556A2 (es) | Composición farmacéutica | |
| PE20091556A1 (es) | Derivado heterociclico fusionado y su uso | |
| PE20121084A1 (es) | Forma de dosificacion farmaceutica para administracion oral de un inhibidor de la familia bcl-2 | |
| CL2019003857A1 (es) | Composiciones y métodos de uso de 2-(4-clorofenil)-n-((2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolin-5-il)metil)-2,2-difluoroacetamida solicitudes relacionadas. | |
| PE20240048A1 (es) | Forma cristalina i del compuesto agonista de receptor de melanocortina y metodo de preparacion para la misma | |
| PE20120561A1 (es) | Compuestos que modulan selectivamente el receptor cb2 | |
| PE20220016A1 (es) | Inhibidores y metodos de uso de kcnt1 | |
| PE20110684A1 (es) | Agonistas de los receptores de la melanocortina | |
| PE20240124A1 (es) | Forma cristalina ii del compuesto agonista de receptor de melanocortina y metodo de preparacion para la misma | |
| PE20200740A1 (es) | Analogos de benzoazepina como agentes inhibidores de la tirosina cinasa de bruton | |
| CO6140054A2 (es) | Compuestos de dialquilfenilo con actividad agonista del receptor beta2 adrenergico y antagonista del receptor muscarinico | |
| PE20220219A1 (es) | Analogos de 3-(5-metil-1,3-tiazol-2-il)-n-{(1r)-1-[2-(trifluor-metil)pirimidin-5-il]etil}benzamida | |
| CO2021003391A2 (es) | Dioxociclobutenilamino-3-hidroxi-picolinamidas n-sustituidas útiles como inhibidores de ccr6 | |
| MX2021006724A (es) | Compuestos de halo-alilamina y uso de los mismos. | |
| EA202090119A1 (ru) | Аморфные и кристаллические формы ido-ингибиторов | |
| PE20200960A1 (es) | Inhibidor de receptor del factor de crecimiento epidermico | |
| PE20061049A1 (es) | Compuestos de n-sulfonilaminobencil-2-fenoxiacetamida como antagonistas del receptor de vanilloides tipo 1 (vr1) | |
| EA202190064A1 (ru) | Цианотриазоловые соединения и варианты их применения | |
| PE20221630A1 (es) | Derivado de amino arilo novedoso util como inhibidor de diacilglicerol aciltransferasa 2 y uso del mismo | |
| AR088838A1 (es) | Derivados de imidazol como inhibidores del virus de la hepatitis c |